This randomized clinical trial compared acetaminophen and ibuprofen for symptom management in children with pyelonephritis. Both medications reduced fever, whereas ibuprofen was associated with greater improvement in several symptoms, including dysuria, abdominal pain, urinary urgency, chills, incontinence, diarrhea, and loss of appetite. These findings suggest potential differences in their symptomatic effects.
Previous studies have compared acetaminophen and ibuprofen for fever and pain management in children. Perrott et al. reported that ibuprofen may provide greater short-term fever reduction, whereas evidence regarding comparative analgesic efficacy was less conclusive (
14). Similarly, a systematic review by Tan et al. found that ibuprofen was associated with lower temperatures during the first 24 hours and greater pain reduction at 4 - 24 hours in children younger than two years (
15). Although these findings broadly support the results of the present study, previous research was not specific to pediatric pyelonephritis. Therefore, the current trial provides additional evidence regarding the comparative effects of these medications on symptoms associated with this infection.
Previous systematic reviews have generally reported comparable fever-reducing effects for acetaminophen and ibuprofen in children, although ibuprofen may offer additional analgesic and anti-inflammatory benefits. The similar fever control observed in this study is consistent with this evidence, whereas the reported differences in other symptoms warrant further investigation.
This trial evaluated the medications individually and did not assess combined or alternating regimens. Such approaches may increase dosing complexity and the risk of medication errors. Therefore, the findings do not support the routine use of combined or alternating therapy. Further research is needed to confirm these results and assess their clinical significance in pediatric pyelonephritis.
Fever reduction did not differ significantly between the two treatment groups, indicating comparable antipyretic efficacy of acetaminophen and ibuprofen. This observation is consistent with previous studies in pediatric populations showing similar temperature-lowering effects for both drugs when administered at appropriate therapeutic doses (
13). Because fever is a cardinal symptom of pyelonephritis and often a primary concern for caregivers, the comparable antipyretic response suggests that either agent can be used effectively to control fever in children with upper urinary tract infections.
Despite similar antipyretic effects, ibuprofen demonstrated superior efficacy in alleviating several non-febrile symptoms. This difference may be attributable to the pharmacological mechanisms of the two drugs. As a nonsteroidal anti-inflammatory drug, ibuprofen inhibits cyclooxygenase enzymes and reduces prostaglandin-mediated inflammation, which plays a central role in the pathogenesis of renal parenchymal infection and associated pain (
16). In contrast, acetaminophen exerts primarily central analgesic and antipyretic effects, with minimal peripheral anti-inflammatory activity, which may limit its ability to relieve inflammation-driven symptoms such as dysuria and abdominal pain (
16).
The greater improvement in urinary symptoms, including dysuria and urgency, among children receiving ibuprofen is clinically meaningful because these symptoms contribute substantially to discomfort and distress in pediatric pyelonephritis. Similar findings have been reported in studies evaluating NSAIDs for inflammatory pain conditions in children, in which ibuprofen demonstrated superior analgesic effects compared with acetaminophen (
17,
18). Improved symptom relief may also explain the observed benefits in appetite and overall well-being in the ibuprofen group, as pain and systemic inflammation are known contributors to anorexia and malaise during acute infections (
19,
20).
Gastrointestinal symptoms were generally mild in both groups, and no serious adverse effects were reported. Vomiting occurred only in the acetaminophen group, although the difference was not statistically analyzed because of its low frequency. Previous large-scale studies have shown that both acetaminophen and ibuprofen have favorable safety profiles in children when used short term and at recommended doses (
21). Concerns regarding NSAID-associated renal adverse effects, particularly in the setting of dehydration or pre-existing renal disease, have been raised in earlier studies (
8,
22). However, no evidence of renal complications was observed in the present study, likely because children with chronic kidney disease were excluded and participants were carefully monitored clinically.
The findings of this trial have potential implications for symptomatic management strategies in pediatric pyelonephritis. Improved symptom control may enhance patient comfort, reduce caregiver anxiety, and improve adherence to antibiotic regimens, thereby supporting recovery. The results suggest that ibuprofen may be a preferable option for children with prominent inflammatory or pain-related symptoms, provided that contraindications are absent.
The study's strengths include its randomized prospective design, direct comparison of two commonly used medications, and assessment of multiple clinically relevant symptoms. Comparable baseline characteristics between groups also supported the treatment comparisons.
Both acetaminophen and ibuprofen effectively reduced fever, whereas ibuprofen was associated with greater improvement in several additional symptoms. However, these findings should be interpreted cautiously in light of potential renal risks and the need for confirmation in larger studies.
Current pediatric pyelonephritis guidelines emphasize timely diagnosis, appropriate antibiotic therapy, hydration, and prevention of renal complications, with limited specific recommendations regarding the choice of antipyretic or analgesic. By directly comparing acetaminophen and ibuprofen, this study contributes preliminary evidence to an area requiring further investigation.
Overall, the results suggest that ibuprofen may offer additional symptomatic benefits in children with pyelonephritis. Nevertheless, treatment decisions should be individualized, particularly for children at risk of dehydration or impaired renal function. Further well-designed trials are needed to confirm these findings and establish evidence-based recommendations for symptomatic management.
The early diagnosis and proper treatment of pyelonephritis can prevent morbidity by children. Furthermore, overuse or misuse of analgesics in management of this issue could lead to increasing the complications by the primary care providers. A way to proper management of children with such disease is using guidelines and educating parents about the best use of analgesics. Furthermore, guidelines can be helping to physicians to proper management, as see in the precise antibiotic using in various infection disease.
5.1. Study Limitations
This study has several limitations. Its single-center design may restrict generalizability, whereas the single-blind design may have introduced reporting bias. Multiple secondary outcomes were analyzed without adjustment for multiple comparisons, increasing the risk of false-positive findings. The relatively small sample also limited the precision of treatment comparisons and safety assessments. Furthermore, the study evaluated short-term outcomes only and did not assess long-term renal complications or combined and alternating antipyretic regimens. Larger, multicenter, double-blind trials with appropriate statistical adjustments and extended follow-up are needed to confirm these findings and clarify the safety and efficacy of NSAIDs in children with pyelonephritis.
5.2. Conclusions
In this randomized clinical trial, both acetaminophen and ibuprofen effectively reduced fever in children with pyelonephritis. However, ibuprofen provided superior improvement in multiple clinically relevant symptoms, including dysuria, abdominal pain, urinary urgency, chills, incontinence, diarrhea, and appetite loss. These findings suggest that ibuprofen may be a more effective option for symptom management in pediatric pyelonephritis, particularly when inflammatory or pain-related symptoms predominate. Careful patient selection and monitoring remain essential to minimize potential adverse effects. Further multicenter studies with long-term follow-up are warranted to confirm these results and evaluate the impact of NSAID therapy on renal outcomes.